Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems
Author's Department
Chemistry Department
Second Author's Department
Chemistry Department
Find in your Library
https://doi.org/10.1038/s41531-025-01081-1
Document Type
Research Article
Publication Title
Npj Parkinson S Disease
Publication Date
12-1-2025
doi
10.1038/s41531-025-01081-1
Abstract
Parkinson’s Disease (PD) involves degeneration of dopamine-producing neurons, mitochondrial dysfunction, alpha-synuclein aggregation, neuroinflammation, and gut-brain axis disturbances. Despite the availability of pharmacological treatments, these interventions fail to prevent disease progression due to their limited ability to penetrate the blood-brain barrier (BBB) and systemic side effects. Phytochemicals, known for their antioxidant and neuroprotective properties, offer a complementary approach to PD treatment. However, their therapeutic potential is limited by rapid metabolism and poor bioavailability. Several nanoparticles were suggested to enhance the stability and bioavailability of therapeutic agents while enabling controlled release and improved BBB penetration. This review is focused on the use of poly (lactic-co-glycolic acid) (PLGA)-based nanosystem as advanced drug delivery carriers for PD due to its versatility, safety, biodegradability, and extensive studies which evaluated the use of PLGA for drug delivery. It also evaluates their use for encapsulating pharmacological drugs such as dopamine agonists, dopamine precursors, COMT inhibitors, and MAO-B inhibitors, addressing the limitations of conventional therapies. Additionally, the review highlights the utility of PLGA nanoparticles in delivering phytochemicals with neuroprotective effects such as polyphenols, flavonoids, and coumarins to overcome challenges associated with their solubility and stability and ultimately enhance their activities for managing PD. (Figure presented.)
Recommended Citation
APA Citation
Lababidi, J.
&
Azzazy, H.
(2025). Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems. Npj Parkinson S Disease, 11(1),
https://doi.org/10.1038/s41531-025-01081-1
MLA Citation
Lababidi, Jude Majed, et al.
"Revamping Parkinson’s disease therapy using PLGA-based drug delivery systems." Npj Parkinson S Disease, vol. 11, no. 1, 2025
https://doi.org/10.1038/s41531-025-01081-1
